Nosopharm
Nosopharm is a French anti-infective drug R&D biotech founded in 2009 in Nîmes, operating with 1–10 employees and approximately $5 million in cumulative early-stage equity funding from French life-sciences investors.
- Company typePrivate
- Founded2009
- HeadquartersNîmes, France
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nosopharm does
Nosopharm is a French biotechnology company founded in 2009 and headquartered in Nîmes, France, focused on the research and development of anti-infective drugs. The firm operates as a small, privately-held R&D-stage organization with between one and ten employees, working in the pre-clinical or early-stage anti-infective drug discovery space. To date, Nosopharm has raised approximately $5 million across three equity rounds between 2013 and 2018 from French life-sciences investors including Bpifrance, Alto Invest, Auriga Partners, and KREAXI, a funding profile consistent with an early-stage European biotech sustaining an ongoing R&D program. The company has not disclosed pricing, products, or commercial revenue mechanics, consistent with a pre-clinical status, and its go-to-market model is implicitly the typical biotech path of internal discovery followed by out-licensing or partnership with larger pharmaceutical companies once candidates advance.
A material data-quality flag: the company's registered web domain (nosopharm.com) currently serves Indonesian-language affiliate content about online gambling platforms (casino, slots, lottery/togel, sports betting), which is unrelated to anti-infective drug R&D. This discrepancy most likely reflects domain repurposing, parking, or unauthorized scraping rather than a legitimate business pivot by the biotech. Investors should independently verify domain control, brand protection, and any reputational or cybersecurity exposure before any transaction.
The leadership team comprises co-founder and CSO Maxime Gualtieri and co-founder and CEO Philippe Villain-Guillot, consistent with a scientific founder profile typical of a French academic-spinout biotech. No management hires, board changes, or other post-2018 corporate actions are disclosed in the available data.
Nosopharm firmographics
Firmographics- Name
- Nosopharm
- Website
- https://nosopharm.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nosopharm is a French anti-infective drug R&D biotech founded in 2009 in Nîmes, operating with 1–10 employees and approximately $5 million in cumulative early-stage equity funding from French life-sciences investors.
- Ownership category
- akta.pro rank
Nosopharm industry classification
Industry- Product category
- Anti-infective Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industries
- Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG), Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD)
Keywords
Where Nosopharm is headquartered
LocationHeadquarters
- HQ city
- Nîmes
- HQ country
- France
- HQ region
- Europe
Markets served
Nosopharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Marketing channels1 record
Nosopharm product offering
Product offeringCore offering
Nosopharm is a French biotechnology company founded in 2009 that researches and develops novel anti-infective drugs. Its work focuses on discovering new antibiotic compounds, exploiting biodiversity from uncultured microorganisms to address the growing problem of antimicrobial resistance.
Differentiator
Problem solved
Functional benefit
Products and services
- Anti-infective drug candidates (R&D pipeline) Pre-clinical and discovery-stage anti-infective drug candidates being developed by Nosopharm to address bacterial infections and antimicrobial resistance. Intended for future out-licensing or partnering with pharmaceutical companies.
Companies that use Nosopharm
Customer profileIdeal customer profiles1 record
Nosopharm technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Nosopharm partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights1 record
Nosopharm competitors and assessment
Company assessmentDirect peers
- Antabio: French anti-infective biotech developing novel antibiotics against WHO priority pathogens; geographically and thematically the closest comparable to Nosopharm as a France-based, privately funded preclinical anti-infective discovery company.
- Mutabilis: France-headquartered biotech discovering novel antibacterial compounds; same stage, geography, and therapeutic focus as Nosopharm and a natural peer for partnership and funding competition.
- Iterum Therapeutics: Clinical-stage anti-infective company developing novel antibiotics for multi-drug resistant infections; comparable therapeutic mission, though at a more advanced clinical stage than Nosopharm.
- Nabriva Therapeutics: Specialty anti-infective company focused on pleuromutilin antibiotics; directly comparable as a developer of new chemical-class antibiotics targeting resistant pathogens.
- Cidara Therapeutics: Clinical-stage anti-infective biotech developing novel antimicrobial agents including Cloudbreak antiviral-antibody conjugates; comparable anti-infective innovator model.
Emerging players
- Vedanta Biosciences: Microbiome-derived therapeutics company developing defined bacterial consortia for infectious and immune-mediated diseases; comparable as a microbe-sourced drug discovery platform relevant to Nosopharm's anti-infective pipeline.
Broad incumbents
- Paratek Pharmaceuticals: Commercial-stage anti-infective company (tetracycline class), an established player in the novel antibiotic space demonstrating both the regulatory pathway and commercial challenges typical for this category.
- Evotec (Anti-infectives platform): Large CRO/drug-discovery platform with an active anti-infectives unit and multiple partnerships in AMR; a relevant incumbent comparator for discovery-stage anti-infective platforms.
- Debiopharm: Swiss pharma company with an established anti-infective franchise and active investment in novel antibiotic R&D; relevant as a strategic partner / acquirer profile for an early French anti-infective biotech.
Others
- GARDP (Global Antibiotic R&D Partnership): Not-for-profit R&D organization funding and partnering with antibiotic developers to address AMR; relevant ecosystem participant Nosopharm could engage for non-dilutive funding and late-stage development.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Nosopharm social profiles
Digital presenceNosopharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nosopharm leadership team
Management profileNumber of profiles
Profiles2 records
Nosopharm funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nosopharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nosopharm
What does Nosopharm do?
Nosopharm is a French biotechnology company founded in 2009 that researches and develops novel anti-infective drugs. Its work focuses on discovering new antibiotic compounds, exploiting biodiversity from uncultured microorganisms to address the growing problem of antimicrobial resistance.
Is Nosopharm a public or private company?
Nosopharm is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nosopharm founded?
Nosopharm was founded in 2009. It employs 1 to 10 people.
Where is Nosopharm based?
Nosopharm is headquartered in Nîmes, France, in the Europe region.
Who are Nosopharm's main competitors?
Direct peers on record are Antabio, Mutabilis, Iterum Therapeutics, Nabriva Therapeutics and Cidara Therapeutics. Vedanta Biosciences is listed as an emerging player. Broad incumbents are Paratek Pharmaceuticals, Evotec (Anti-infectives platform) and Debiopharm. GARDP (Global Antibiotic R&D Partnership) is listed as an others.
Does Nosopharm have an API?
No public API is recorded for Nosopharm.
What industry is Nosopharm in?
Nosopharm's product category is Anti-infective Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAAAFAG, Microbiome Modulating Small Molecules & Antibiotic Alternatives. Its NAICS code is 541714 and its SIC code is 2834.